biote Corp
NASDAQ:BTMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
biote Corp
NASDAQ:BTMD
|
US |
|
K
|
Kiatnakin Phatra Bank PCL
SET:KKP
|
TH |
|
B
|
Barunson Entertainment & Arts Corp
KOSDAQ:035620
|
KR |
|
Xunlei Ltd
NASDAQ:XNET
|
CN |
|
EFORT Intelligent Equipment Co Ltd
SSE:688165
|
CN |
|
D
|
Daido Group Ltd
HKEX:544
|
HK |
|
Prima Andalan Mandiri Tbk PT
IDX:MCOL
|
ID |
|
Match Group Inc
NASDAQ:MTCH
|
US |
|
K
|
Kernex Microsystems (India) Ltd
NSE:KERNEX
|
IN |
|
Kalyani Steels Ltd
NSE:KSL
|
IN |
|
VLS Finance Ltd
BSE:511333
|
IN |
|
Jupiter Fund Management PLC
F:4JF
|
UK |
|
F
|
F-Secure Oyj
OMXH:FSECURE
|
FI |
|
J
|
JILIN QUANYANGQUAN Co Ltd
SSE:600189
|
CN |
|
D
|
Danel Adir Yeoshua Ltd
TASE:DANE
|
IL |
|
S
|
Sonokong Co Ltd
KOSDAQ:066910
|
KR |
|
Houlihan Lokey Inc
NYSE:HLI
|
US |
|
H
|
Henan Shijia Photons Technology Co Ltd
SSE:688313
|
CN |
|
Viva Energy Group Ltd
ASX:VEA
|
AU |
|
M
|
musicMagpie PLC
LSE:MMAG
|
UK |
biote Corp
biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas. The company went IPO on 2021-03-02. The firm provides components to enable Biote-certified practitioners to establish, build, and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. Its Biote Method is a comprehensive, end-to-end practice-building platform that provides Biote-certified practitioners with components specifically developed for practitioners in the hormone optimization space, such as Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The firm trains practitioners how to identify and treat early indicators of hormone-related aging conditions. The company also sells a complementary Biote-branded line of dietary supplements.
biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas. The company went IPO on 2021-03-02. The firm provides components to enable Biote-certified practitioners to establish, build, and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. Its Biote Method is a comprehensive, end-to-end practice-building platform that provides Biote-certified practitioners with components specifically developed for practitioners in the hormone optimization space, such as Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The firm trains practitioners how to identify and treat early indicators of hormone-related aging conditions. The company also sells a complementary Biote-branded line of dietary supplements.
Revenue: Q4 revenue was $46.4 million, down 6.9% YoY, driven by a 13% decline in procedure revenue to $31.8 million while dietary supplement revenue grew 16% to $11.7 million.
Margins: Gross margin fell to 68.0% (from 71.8%) largely because of a $1.3 million inventory charge tied to a voluntary pellet recall; adjusted EBITDA fell to $11.7 million (25.2% margin).
Recall & manufacturing: Management initiated a voluntary partial recall and is working with the FDA; Asteria (internal 503B site) accounts for roughly 50% of pellet supply versus a peak of 54% in Q3.
Commercial actions: Company rebuilt its commercial organization, grew the salesforce to over 90 and plans to expand to ~120 reps in 2026 to drive new clinic starts and reduce attrition.
Investments & near-term impact: Biote will invest materially in sales and its technology platform in 2026; management expects these investments to pressure adjusted EBITDA in 2026 but to drive procedure revenue improvement starting in H2.
2026 outlook: Revenues forecast above $190 million and adjusted EBITDA greater than $38 million; procedure revenue expected to decline mid- to high-single digits in H1 then return to YoY growth in H2, supplements to grow mid- to high-single digits.
